Effects of α-difluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer

Elzbieta Izbicka; Robert T. Streeper; I. Tien Yeh; Oredius Pressley; Michael Grant; J. Valerie R. Andrews; Joseph Kuhn; Joyce O'Shaughnessy

Effects of α-difluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer

Elzbieta Izbicka, Robert T. Streeper, I. Tien Yeh, Oredius Pressley, Michael Grant, J. Valerie R. Andrews, Joseph Kuhn, Joyce O'Shaughnessy

Pathology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Aim: To examine changes in biomarkers expressed in breast tumors in response to patient treatment with the polyamine synthesis inhibitor α-difluoromethylornithine (DFMO). Patients and Methods: The expression of Ki-67 (MIB-1), matrix metalloproteinases (MMP) 2 and 9, urokinase-type plasminogen activator (uPA) were examined by immunohistochemistry in breast tissue specimens (controls: n=15, 13 evaluable, and DFMO group; n=27, 21 evaluable). Apoptosis was evaluated by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). Results: Significant increases in apoptosis, MMP-9 and uPA (tumor) were observed in 7 patients ≥50 years who received DFMO for ≥14 days relative to patients <50 years and/or who received <14 days of treatment (n=11). No other measured characteristics, including tumor estrogen and progesterone receptor status, hormone replacement therapy history, histopathological characteristics or tumor grade were correlated with these biomarker changes. Conclusion: Unexpected correlation of proapoptotic DFMO activity in postmenopausal women with breast cancer warrants further study.

Original language	English (US)
Pages (from-to)	2263-2269
Number of pages	7
Journal	Anticancer Research
Volume	30
Issue number	6
State	Published - Jun 1 2010

Keywords

α-difluoromethylornithine
Apoptosis
Biomarker
Breast cancer
DFMO
Invasion
Proliferation

ASJC Scopus subject areas

Oncology
Cancer Research

Fingerprint Dive into the research topics of 'Effects of α-difluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer'. Together they form a unique fingerprint.

Cite this

Effects of α-difluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer. / Izbicka, Elzbieta; Streeper, Robert T.; Yeh, I. Tien; Pressley, Oredius; Grant, Michael; Andrews, J. Valerie R.; Kuhn, Joseph; O'Shaughnessy, Joyce.

In: Anticancer Research, Vol. 30, No. 6, 01.06.2010, p. 2263-2269.

Research output: Contribution to journal › Article › peer-review

@article{fbedf9f9b9cb4413875aa15b00dda9b7,

title = "Effects of α-difluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer",

abstract = "Aim: To examine changes in biomarkers expressed in breast tumors in response to patient treatment with the polyamine synthesis inhibitor α-difluoromethylornithine (DFMO). Patients and Methods: The expression of Ki-67 (MIB-1), matrix metalloproteinases (MMP) 2 and 9, urokinase-type plasminogen activator (uPA) were examined by immunohistochemistry in breast tissue specimens (controls: n=15, 13 evaluable, and DFMO group; n=27, 21 evaluable). Apoptosis was evaluated by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). Results: Significant increases in apoptosis, MMP-9 and uPA (tumor) were observed in 7 patients ≥50 years who received DFMO for ≥14 days relative to patients <50 years and/or who received <14 days of treatment (n=11). No other measured characteristics, including tumor estrogen and progesterone receptor status, hormone replacement therapy history, histopathological characteristics or tumor grade were correlated with these biomarker changes. Conclusion: Unexpected correlation of proapoptotic DFMO activity in postmenopausal women with breast cancer warrants further study.",

keywords = "α-difluoromethylornithine, Apoptosis, Biomarker, Breast cancer, DFMO, Invasion, Proliferation",

author = "Elzbieta Izbicka and Streeper, {Robert T.} and Yeh, {I. Tien} and Oredius Pressley and Michael Grant and Andrews, {J. Valerie R.} and Joseph Kuhn and Joyce O'Shaughnessy",

year = "2010",

month = jun,

day = "1",

language = "English (US)",

volume = "30",

pages = "2263--2269",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "6",

}

TY - JOUR

T1 - Effects of α-difluoromethylornithine on markers of proliferation, invasion, and apoptosis in breast cancer

AU - Izbicka, Elzbieta

AU - Streeper, Robert T.

AU - Yeh, I. Tien

AU - Pressley, Oredius

AU - Grant, Michael

AU - Andrews, J. Valerie R.

AU - Kuhn, Joseph

AU - O'Shaughnessy, Joyce

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Aim: To examine changes in biomarkers expressed in breast tumors in response to patient treatment with the polyamine synthesis inhibitor α-difluoromethylornithine (DFMO). Patients and Methods: The expression of Ki-67 (MIB-1), matrix metalloproteinases (MMP) 2 and 9, urokinase-type plasminogen activator (uPA) were examined by immunohistochemistry in breast tissue specimens (controls: n=15, 13 evaluable, and DFMO group; n=27, 21 evaluable). Apoptosis was evaluated by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). Results: Significant increases in apoptosis, MMP-9 and uPA (tumor) were observed in 7 patients ≥50 years who received DFMO for ≥14 days relative to patients <50 years and/or who received <14 days of treatment (n=11). No other measured characteristics, including tumor estrogen and progesterone receptor status, hormone replacement therapy history, histopathological characteristics or tumor grade were correlated with these biomarker changes. Conclusion: Unexpected correlation of proapoptotic DFMO activity in postmenopausal women with breast cancer warrants further study.

AB - Aim: To examine changes in biomarkers expressed in breast tumors in response to patient treatment with the polyamine synthesis inhibitor α-difluoromethylornithine (DFMO). Patients and Methods: The expression of Ki-67 (MIB-1), matrix metalloproteinases (MMP) 2 and 9, urokinase-type plasminogen activator (uPA) were examined by immunohistochemistry in breast tissue specimens (controls: n=15, 13 evaluable, and DFMO group; n=27, 21 evaluable). Apoptosis was evaluated by terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). Results: Significant increases in apoptosis, MMP-9 and uPA (tumor) were observed in 7 patients ≥50 years who received DFMO for ≥14 days relative to patients <50 years and/or who received <14 days of treatment (n=11). No other measured characteristics, including tumor estrogen and progesterone receptor status, hormone replacement therapy history, histopathological characteristics or tumor grade were correlated with these biomarker changes. Conclusion: Unexpected correlation of proapoptotic DFMO activity in postmenopausal women with breast cancer warrants further study.

KW - α-difluoromethylornithine

KW - Apoptosis

KW - Biomarker

KW - Breast cancer

KW - DFMO

KW - Invasion

KW - Proliferation

UR - http://www.scopus.com/inward/record.url?scp=77955075875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955075875&partnerID=8YFLogxK

M3 - Article

C2 - 20651378

AN - SCOPUS:77955075875

VL - 30

SP - 2263

EP - 2269

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -